<DOC>
	<DOCNO>NCT00094159</DOCNO>
	<brief_summary>The purpose study determine whether SNS-595 give intravenously weekly 3 week safe .</brief_summary>
	<brief_title>Safety Assessment Weekly Intravenous Infusions SNS-595 Treatment Solid Tumors</brief_title>
	<detailed_description>Other objective study include measure pharmacokinetics ( long drug measure blood ) determine dose dose schedule next phase study SNS-595 .</detailed_description>
	<criteria>Must give write informed consent 18 year age Advanced solid malignant tumor Tumor measure evaluated Blood test within standard limit Normal blood coagulation ECOG Performance Status equal 0 1 Hemoglobin &gt; = 9.0 g/dL Absolute Neutrophil Count &gt; = 1,500 Platelets &gt; = 100,000 Calculated measure creatinine clearance &lt; 50 mL/min Serum creatinine &lt; = 1.5 time upper limit normal ( ULN ) AST , ALT , Alkaline Phosphatase &lt; 3 time ULN except hepatic involvement AST , ALT , Alkaline Phosphatase &lt; = 5 time ULN Total Bilirubin &lt; = 2 mg/dL Prior exposure SNS595 Pregnant breastfeeding . Women childbearing potential unwilling use approve , effective mean contraception accord institution â€™ standard . Heart attack , stroke/TIA blood clot event ( deep vein thrombosis pulmonary embolus ) within 6 month screen visit . Requires kidney dialysis ( hemodialysis peritoneal ) . Known bleed disorder ( i.e. , hemophilia , von Willebrand Disease , coagulopathy , etc. ) . Received investigational agent prior chemotherapy immunotherapy within 28 day first dose SNS595 Receiving therapeutic anticoagulation therapy ( coumadin , heparin , etc. ) . Currently receive corticosteroid ( inhaled steroid breathe disease allow ) seizure medication . Any medical , psychological , social condition , opinion Principal Investigator , would contraindicate patient 's participation clinical trial due safety compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>